Materias dentro de su búsqueda.
Mostrando 1,581 - 1,600 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.21s Limitar resultados
  1. 1581
    “…FUNDING: Cancer Research UK, the National Health and Medical Research Council Australia, Breast Cancer Research Foundation, Sanofi Aventis, and AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
  2. 1582
    Publicado 2020
    “…FUNDING: Wellcome Trust, AstraZeneca Young Health Programme, EU.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants
  3. 1583
    “…Pannaraj, MD, MPH, AstraZeneca (Grant/Research Support)Pfizer (Grant/Research Support)Sanofi Pasteur (Advisor or Review Panel member)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children’s Hospitals in the United States. 2014–2019
  4. 1584
    por Sattui, Sebastian Eduardo, Liew, Jean W, Kennedy, Kevin, Sirotich, Emily, Putman, Michael, Moni, Tarin T, Akpabio, Akpabio, Alpízar-Rodríguez, Deshiré, Berenbaum, Francis, Bulina, Inita, Conway, Richard, Singh, Aman Dev, Duff, Eimear, Durrant, Karen L, Gheita, Tamer A, Hill, Catherine L, Howard, Richard A, Hoyer, Bimba F, Hsieh, Evelyn, El Kibbi, Lina, Kilian, Adam, Kim, Alfred Hyoungju, Liew, David F L, Lo, Chieh, Miller, Bruce, Mingolla, Serena, Nudel, Michal, Palmerlee, Candace A, Singh, Jasvinder A, Singh, Namrata, Ugarte-Gil, Manuel Francisco, Wallace, John, Young, Kristen J, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Harrison, Carly, Larché, Maggie, Levine, Mitchell, Foster, Gary, Thabane, Lehana, Rider, Lisa G, Hausmann, Jonathan S, Simard, Julia F, Sparks, Jeffrey A
    Publicado 2021
    “…Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
  5. 1585
    por Falsey, Ann R., Sobieszczyk, Magdalena E., Hirsch, Ian, Sproule, Stephanie, Robb, Merlin L., Corey, Lawrence, Neuzil, Kathleen M., Hahn, William, Hunt, Julie, Mulligan, Mark J., McEvoy, Charlene, DeJesus, Edwin, Hassman, Michael, Little, Susan J., Pahud, Barbara A., Durbin, Anna, Pickrell, Paul, Daar, Eric S., Bush, Larry, Solis, Joel, Carr, Quito Osuna, Oyedele, Temitope, Buchbinder, Susan, Cowden, Jessica, Vargas, Sergio L., Benavides, Alfredo Guerreros, Call, Robert, Keefer, Michael C., Kirkpatrick, Beth D., Pullman, John, Tong, Tina, Isaacs, Margaret Brewinski, Benkeser, David, Janes, Holly E., Nason, Martha C., Green, Justin A., Kelly, Elizabeth J., Maaske, Jill, Mueller, Nancy, Shoemaker, Kathryn, Takas, Therese, Marshall, Richard P., Pangalos, Menelas N., Villafana, Tonya, Gonzalez-Lopez, Antonio
    Publicado 2021
    “…CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.)…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
  6. 1586
    “…Both Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccines are used in Saudi Arabia and in many parts of the world. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
  7. 1587
    “…Younger age, being female, prior SARS-CoV-2 infection, and receiving the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vs BNT162b2 (Pfizer-BioNTech) vaccine were associated with experiencing a reaction after the first vaccine dose. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
  8. 1588
    “…DISCLOSURES: Ravi Jhaveri, MD, AstraZeneca (Consultant)Dynavax (Consultant)Elsevier (Other Financial or Material Support, Editorial stipend as Co-EiC, Clinical Therapeutics)Hologic (Consultant)Seqirus (Consultant)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    777. Implementation of Antimicrobial Impregnated Catheters to Reduce Central Line Associated Bloodstream Infections (CLABSI) in a Pediatric Setting
  9. 1589
    “…Ethiopia began on March 13, 2021, to vaccinate healthcare workers (HCWs) for COVID-19 with the AstraZeneca vaccine. However, willingness to be vaccinated depends to a large extent on factors beyond the availability of vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Knowledge, attitudes, and perceptions of COVID-19 vaccine and refusal to receive COVID-19 vaccine among healthcare workers in northeastern Ethiopia
  10. 1590
    “…This study evaluated the effect of prior vaccination with either Oxford Astra Zeneca’s Covishield™ or Bharath Biotech’s Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in India. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of prior vaccination with Covishield(TM) and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study
  11. 1591
    “…Another case study described a 77-year-old male patient who developed generalized pruritis and bullae on erythematous bases one day after receiving the AstraZeneca COVID-19 vaccination. This new-onset bullous pemphigoid phenomenon has also been observed with other vaccinations such as rabies and swine flu. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report
  12. 1592
    “…One hundred and ninety-eight GBS cases occurred within 6 weeks of the first-dose COVID-19 vaccination in England [0.618 cases per 100,000 vaccinations; 176 ChAdOx1 nCoV-19 (AstraZeneca), 21 tozinameran (Pfizer) and one mRNA-1273 (Moderna)]. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database
  13. 1593
    “…EXPOSURE: Vaccination with Covid-19 vaccines available during the study period: Gam-COVID-Vac (Sputnik), ChAdOx1 nCoV-19 (AstraZeneca/Oxford or Covishield), BBIBP-CorV (Beijing Institute of Biological Products) (Sinopharm). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Thrombotic events following Covid-19 vaccines compared to Influenza vaccines
  14. 1594
    “…METHODS: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
  15. 1595
    “…Nous rapportons le cas d’une patiente de 35 ans sans antécédent notable, qui a présenté un épisode neurologique dans les suites d’une vaccination ChAdOx1 nCoV-19 (COVISHIELD AstraZeneca) contre le SARS-CoV-2. Une semaine après la vaccination, la patiente a présenté des céphalées avec nausées et douleurs rétro-orbitaires sans anomalie à la consultation d’ophtalmologie, suivie une semaine plus tard d’une rétention aiguë d’urine spontanément résolutive. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Myélite, névrite optique et hypertension intracrânienne dans le cadre d’une maladie à anti-MOG après vaccination anti-COVID-19 : à propos d’un cas et revue de la littérature
  16. 1596
    “…Deux cas similaires ont été rapportés après le vaccin AstraZeneca*. Nous avons retenu le diagnostic de réaction dysimmunitaire post-vaccinale devant un délai de survenue compatible, la présence de bandes oligoclonales dans le LCR, un hypermétabolisme putaminal droit en TEP-FDG, la normalité des autres explorations et l’efficacité des corticoïdes. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hémichorée-hémiballisme post-vaccination Covid-19 : à propos d’un cas
  17. 1597
    “…A high percentage of females and those who received the AstraZeneca vaccine stated that their side effects affected their work performance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Side Effects of COVID-19 Vaccines and Its Association With ABO Blood Type Among the General Surgeons in Saudi Arabia
  18. 1598
    “…OBJECTIVE: To assess the antibody response to disease-modifying antirheumatic drug (DMARD) therapy after the first and second dose of the ChAdOx1nCov-19 (AstraZeneca (AZ)) and BNT162b (Pfizer) vaccines in patients with immune-mediated inflammatory disease (IMID) compared with controls and if withholding therapy following the first vaccination dose has any effect on seroconversion and SARS-CoV-2 antibody (Ab) levels. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)
  19. 1599
    “…BACKGROUND: Due to safety signals after vaccination with COVID-19 vector vaccines, several states recommended to complete the primary immunization series in individuals having received one dose of ChAdOx1 (AstraZeneca) with an mRNA vaccine. However, data on safety and reactogenicity of this heterologous regimen are still scarce. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
  20. 1600
    “…RÉSULTATS: Nous avons colligé 10 patients, l’âge moyens était de 35 ± 14,3 ans, le sex-ratio était à 2,3, 60 % des patients ont reçus le vaccin Sinopharm (BIBP COVID-19 vaccine), 20 % Astra Zeneca (ChAdOx1-S [recombinant] COVID-19 vaccine) et 20 % Pfizer-BioNTech (BNT162b2), l’apparition des symptômes était dans 80 % des cas après la 2ème dose, et dans 20 % des cas après la 1(re) dose, avec un délai moyen de 4,5 ± 3,6 semaines, les diagnostics après ponction biopsie rénale ainsi que l’évolution sont exposés dans le Tableau 1. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Néphropathies post-vaccination anti-Sars Cov2 : lien de causalité ou bien simple coïncidence ? expérience du service de néphrologie de Marrakech
Herramientas de búsqueda: RSS